Elvira Sbragia

Dr. Elvira Sbragia

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
MCMaria Cellerino
Maria Cellerino
CCChristian Cordano
Christian Cordano
GBGiacomo Boffa
Giacomo Boffa
GBGiulia Bommarito
Giulia Bommarito
MPMaria Petracca
Maria Petracca
MIMatilde Inglese
Matilde Inglese
Objective To investigate whether inner nuclear layer (INL) thickness as assessed with optical coherence tomography differs between patients with progressive MS (P-MS) according to age and disease activity. Methods In this retrospective longitudinal analysis, differences in terms of peripapillary retinal nerve fiber layer (pRNFL), ganglion cell layer + inner plexiform layer (GCIPL), INL and T1/T2 lesion volumes (T1LV/T2LV) were assessed between 84 patients with P-MS and 36 sex- and age-matched healthy controls (HCs) and between patients stratified according to age (cut-off: 51 years) and evidence of clinical/MRI activity in the previous 12 months Results pRNFL and GCIPL thickness were significantly lower in patients with P-MS than in HCs (p = 0.003 and p < 0.0001, respectively). INL was significantly thicker in patients aged < 51 years compared to the older ones and HCs (38.2 vs 36.5 and 36.7 μm; p = 0.038 and p = 0.04, respectively) and in those who presented MRI activity (new T2/gadolinium-enhancing lesions) in the previous 12 months compared to the ones who did not and HCs (39.5 vs 36.4 and 36.7 μm; p = 0.003 and p = 0.008, respectively). Recent MRI activity was significantly predicted by greater INL thickness (Nagelkerke R2 0.36, p = 0.001). Conclusions INL thickness was higher in younger patients with P-MS with recent MRI activity, a criterion used in previous studies to identify a specific subset of patients with P-MS who best responded to disease-modifying treatment. If this finding is confirmed, we suggest that INL thickness might be a useful tool in stratification of patients with P-MS for current and experimental treatment choice.

17 May 2020 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
GBG. Boffa
G. Boffa
CLC. Lapucci
C. Lapucci
ESElvira Sbragia
Elvira Sbragia
RVR. Varaldo
R. Varaldo
ARA. M. Raiola
A. M. Raiola
MIM. Inglese
M. Inglese

1 May 2020 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
MCMaria Cellerino
Maria Cellerino
FIFederico Ivaldi
Federico Ivaldi
MPMatteo Pardini*
Matteo Pardini*
GRGianluca Rotta
Gianluca Rotta
GVGemma Vila
Gemma Vila
AUAntonio Uccelli
Antonio Uccelli
Objective To establish cytometry profiles associated with disease stages and immunotherapy in MS. Methods Demographic/clinical data and peripheral blood samples were collected from 227 patients with MS and 82 sex- and age-matched healthy controls (HCs) enrolled in a cross-sectional study at 4 European MS centers (Spain, Italy, Germany, and Norway). Flow cytometry of isolated peripheral blood mononuclear cells was performed in each center using specifically prepared antibody-cocktail Lyotubes; data analysis was centralized at the Genoa center. Differences in immune cell subsets were assessed between groups of untreated patients with relapsing-remitting or progressive MS (RRMS or PMS) and HCs and between groups of patients with RRMS taking 6 commonly used disease-modifying drugs. Results In untreated patients with MS, significantly higher frequencies of Th17 cells in the RRMS population compared with HC and lower frequencies of B-memory/B-regulatory cells as well as higher percentages of B-mature cells in patients with PMS compared with HCs emerged. Overall, the greatest deviation in immunophenotype in MS was observed by treatment rather than disease course, with the strongest impact found in fingolimod-treated patients. Fingolimod induced a decrease in total CD4+ T cells and in B-mature and B-memory cells and increases in CD4+ and CD8+ T-regulatory and B-regulatory cells. Conclusions Our highly standardized, multisite cytomics data provide further understanding of treatment impact on MS immunophenotype and could pave the way toward monitoring immune cells to help clinical management of MS individuals.

19 March 2020 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
GBGiacomo Boffa
Giacomo Boffa
NBNicolò Bruschi
Nicolò Bruschi
MCMaria Cellerino
Maria Cellerino
CLCaterina Lapucci
Caterina Lapucci
GNGiovanni Novi
Giovanni Novi
MIMatilde Inglese
Matilde Inglese

16 August 2019 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
GBG. Boffa
G. Boffa
ATAndrea Tacchino
Andrea Tacchino
ESElvira Sbragia
Elvira Sbragia
SSS. Schiavi
S. Schiavi
ADAmgad Droby
Amgad Droby
MIM. Inglese
M. Inglese

19 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CMClaudia Massarotti
Claudia Massarotti
ESElvira Sbragia
Elvira Sbragia
IGIrene Gazzo
Irene Gazzo
SSSara Stigliani
Sara Stigliani
MIMatilde Inglese
Matilde Inglese
PAPaola Anserini
Paola Anserini
Multiple sclerosis is a chronic disease that may lead to different types of symptoms and disabilities. with the better quality of life and decreased disability due to early diagnosis and the availability of disease-modifying therapies (DMTs), the treating physician is increasingly asked to counsel patients on its effects on fertility and reproduction. In particular, reproductive issues are still scarcely studied and discussed in men. Among the still open questions are the following: (a) Does multiple sclerosis cause infertility per sè? (b) Is multiple sclerosis correlated with conditions that increase the risk of infertility? (c) Do DMTs or other therapies for multiple sclerosis impact gonadal function in men? The aim of this review is to provide an overview on the available literature data about the reproductive issues unique to men with multiple sclerosis, underlining the numerous areas where evidence is lacking and, therefore, the priorities for future research.